ImvivaBio is a clinical-stage biotechnology company pioneering next-generation allogeneic (“off-the-shelf”) CAR-T therapies for autoimmune and hematologic diseases.

Built on one of the world’s most clinically validated allo-CAR-T platforms—with 12 clinical iterations and over 300 patients treated—ImvivaBio combines deep immunology expertise with proven clinical execution.

Lead autoimmune program CTA313 (BCMA/CD19 dual-targeted allo-CAR-T) recently presented at ACR 2025, demonstrated:

• SRI-4 100%, LLDAS 79%, and DORIS 43% remission (n=15)

• 67% Day-28 persistence, which experts noted is likely sufficient for autoimmune indications

• All CRS Grade 1 (38%), with no ICANS or GvHD

CD7 allo-CAR-T program in T-ALL/LBL has treated 100+ patients with 60–70% CR (vs. 20–25% SoC) and received RMAT and Rare Pediatric Disease Designations, advancing toward a registrational Phase 2 in the U.S.